Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
Metabolic Syndrome Resolution Post-hoc analysis of SURPASS trials demonstrated substantial reductions in metabolic syndrome prevalence: Significant improvements in multiple cardiovascular risk factors simultaneously Reductions in blood pressure, improved lipid profiles, and decreased waist circumference Resolution of metabolic syndrome criteria in a substantial proportion of participants Potential long-term cardiovascular benefits from comprehensive metabolic improvements Cardiovascular and Metabolic Comorbidities Heart Failure with Preserved Ejection Fraction (HFpEF) The SUMMIT phase 3 trial evaluated GLP2 in adults with HFpEF and obesity: Statistically significant reduction in heart failure outcomes (composite endpoint) Improvements in heart failure symptoms and physical limitations measured by Kansas City Cardiomyopathy Questionnaire Enhanced exercise capacity as measured by 6-Minute Walk Test Distance Reduction in high-sensitivity C-reactive protein (inflammation marker) These findings established GLP2 as the first incretin therapy to demonstrate benefits on heart failure outcomes in this population
Practical Implications for Patients For patients, these findings are more than academic
This process creates ketones, which are chemicals made by the liver
Only 6% (n=30) were vaccinated against HBV, 92% (n=453) were not vaccinated, and 2.4% (n=12) reported not knowing vaccination status
Phase 2 introduces more variety and brings protein closer to target
Keywords: GLP-1 receptor agonist-related weight loss, massive weight loss, regenerative aesthetics, energy-based devices Introduction Approximately 1.9 billion people are considered overweight, and approximately 650 million adults have obesity
US$ 25.48
US$ 28.86
US$ 29.18
US$ 22.57
US$ 25.64
US$ 23.61
